Stocks on Tech Trader

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: DHR rebounded modestly today to 191.02 but the low-volume green candle inside the recent range doesn't change the bigger picture, so we're staying in cash after exiting the long last week....

Summary: DHR closed lower again at 188.44 on increased volume after failing to hold the bounce, confirming the short-term momentum has shifted and supporting our move to cash....

Summary: DHR's bounce has stalled and reversed with two straight down days, drifting back toward our entry while technical indicators flash sell signals across the board....

Summary: DHR gave back a bit of the prior day's gains on light volume but held above 191 support and stays up nearly 3% from our entry....

Summary: DHR extended its bounce with a solid gap-up day, closing at 195.05 and putting us up nearly 5% from our 186.26 entry in just three days....

Summary: We're up from our 186.26 entry as DHR bounces off the March 12 low with improving price action and volume on the 3/16 session. ...

Summary: Holding LONG as price edged up to 187.28 from 186.26 entry amid deeply oversold RSI 25 near key 186 support, with analyst buy ratings and March price targets around 213 signaling bounce potential despite persistent downtrend....

Summary: Re-entering LONG two days after 3/10 exit at better price 188.1 vs 195.22, deeply oversold RSI 24 near 187 support, with strong buy ratings and high targets outweighing prior downtrend concerns....

Summary: Persistent downtrend in DHR persists below key supports without clear reversal despite oversold RSI 29 and recent AI partnership news, justifying staying in cash after yesterday's exit as risks outweigh potential bounce....

Summary: Exit LONG to CASH—persistent downtrend to 196.93 breaks below 204 support amid investor skepticism on Masimo acquisition track record and sluggish revenue growth below 2022 levels, despite oversold RSI 30.5 signaling potential bounce but lacking catalysts....

Summary: Hold LONG—oversold RSI ~30-35 tests $195 support post-Masimo digestion, Strong Buy consensus $265 PT (36% upside) signals rebound....

Summary: Hold LONG—oversold RSI ~32-42 tests $202 support intact, Strong Buy consensus $253-266 PT (25%+ upside) outweighs ChartMill 0/10 dip post-Masimo digestion....

Summary: Hold LONG—oversold RSI ~35-47 at 204.73 support holds firm, Strong Buy consensus $265 PT (29% upside) outweighs ChartMill 0/10 dip....

Summary: Hold LONG—oversold RSI ~35-42 tests 204 support intact, Strong Buy consensus $265 PT (29% upside) signals dip buy amid no fresh bears....

Summary: Holding LONG as DHR tests key support at 204.22 with oversold RSI 32.6 and positive dividend announcement alongside institutional buying signaling rebound potential; next earnings April 28, 2026....

Summary: Holding LONG as DHR remains oversold at RSI 34.5 near 204.22 support with positive dividend announcement and strong buy consensus signaling rebound potential; next earnings April 28, 2026....

Summary: Holding LONG as DHR stabilizes above 204.22 support with oversold RSI 36.9 signaling continued bounce, positive Masimo deal sentiment and dividend announcement reinforce upside; next earnings April 28, 2026....

Summary: Holding LONG as DHR holds above key 204.22 support with oversold RSI 37.2 signaling bounce, Masimo deal viewed as strategic despite initial dip, Strong Buy consensus with 28% upside; next earnings April 21, 2026....

Summary: Holding LONG as DHR stabilizes above 204.22 support with RSI 37.9 oversold, boosted by recent dividend increase to $1.60 and Guggenheim's $275 PT upgrade amid bioprocessing gains, no new bears; next earnings April 21, 2026....

Summary: Holding LONG as DHR stabilizes at 209.92 above 204.22 support post-Masimo acquisition overreaction, RSI 37.5 signals oversold bounce potential amid accretive deal benefits, no fresh bearish news; next earnings April 21, 2026....

Summary: Holding LONG as DHR stabilizes post-Masimo acquisition overreaction, with price at 210.76 holding above 204.22 bottom, RSI improving to 38, and no fresh bearish catalysts; next earnings April 21, 2026....

Summary: Holding LONG as DHR stabilizes above key support post-Masimo acquisition overreaction, with RSI improving from oversold 30 to 37 and price bouncing from high conviction bottom at 204.22 amid strategic deal benefits; next earnings April 21, 2026....

Summary: Continuing LONG as price stabilizes post-acquisition selloff with oversold RSI 35.9 and bounce from high conviction bottom at 204.22, signaling overreaction to Masimo deal amid strategic benefits and no major negative catalysts; next earnings April 21, 2026....

Summary: Re-entering LONG one day after exit as price bounced from high conviction bottom at 204.22 with oversold RSI 33.9, signaling overreaction to Masimo acquisition news amid strategic benefits and accretive EPS outlook....

Summary: Exiting LONG to CASH as Danaher's $9.9B Masimo acquisition sparked a sharp selloff with bearish options surge, breaking supports near $202 amid oversold RSI 29 but negative MACD divergence; next earnings April 21, 2026....

Summary: Holding LONG as oversold RSI 34 and STO 5.6 signal bounce potential, analysts maintain buy ratings with 20% upside targets, and 2026 revenue growth forecast supports recovery amid stabilizing post-earnings dip; next earnings April 21, 2026....

Summary: Holding LONG amid oversold indicators like STO at 9.6 signaling bounce potential, positive analyst buy ratings with 20% upside targets, and stabilizing price after post-earnings dip, next earnings April 21, 2026....

Summary: Holding LONG as price shows modest recovery from post-earnings dip with oversold STO at 12 signaling potential bounce, stabilizing MACD, recent earnings beat boosting confidence, and analyst optimism for back-loaded 2026 growth, next earnings April 21, 2026....

Summary: Holding LONG as price recovers modestly post-earnings dip with oversold STO signaling bounce, stabilizing MACD, insider share acquisitions boosting confidence, and next earnings April 21, 2026....

Summary: Holding LONG as price edges up slightly from entry amid oversold RSI 38 and STO, bearish but stabilizing MACD, and no fresh negative news outweighing positive earnings beat details, with next earnings April 22, 2026....

Summary: Re-entering LONG soon after 1/30 exit due to better entry price at 216.68 vs 218.89, oversold RSI 37 signaling bounce potential, and positive earnings growth details outweighing prior tepid guidance concerns amid mixed but leaning bullish recent news....

Summary: Post-earnings dip to $216 tests support amid neutral RSI ~47 & negative MACD—ChartMill signals faded momentum, no volume rebound yet....

Summary: Post-earnings stabilization ~$223 lacks upside volume conviction—ChartMill low rating persists, RSI neutral 35-64 signals caution amid healthcare digestion....

Summary: Post-earnings base ~$223 holds but ChartMill 1/10 bearish rating persists, RSI neutral without buy conviction—wait for volume-confirmed rebound....

Summary: Post-earnings stabilization ~$218 lacks bounce momentum—ChartMill bearish 1/10 rating, RSI neutral-sell signals caution....

Summary: Exit LONG post-Q4 beat selloff—stock plunged 4.8% despite EPS $2.23 beat/$2.22 est, tepid guidance signals caution amid neutral RSI 54....

Summary: Hold LONG—pre-earnings Friday strength to $252 +9.3% gain, Canaccord initiates Buy $275, ChartMill momentum unbreakable....

Summary: Hold LONG—Q4 EPS preview $1.70 intact, SunriseTrader trails stops higher on 26wk high base, Q3 13F trims filed late irrelevant....

Summary: Hold LONG—SunriseTrader raises stops on 26-week high breakout over MAs, TD Cowen $270 Buy PT, Q3 13F trims old news pre-earnings....

Summary: Hold LONG—Oppenheimer initiates Outperform $285 record PT, 13F frenzy (Signaturefd +25%), ChartMill momentum obliterates to $249 ATH....

Summary: Hold LONG—UBS initiates Buy $280 street-record PT, 13F torrent (Signaturefd +20%), ChartMill god-mode momentum to $248 ATH....

Summary: Hold LONG—Deutsche Bank initiates Buy $275 street-high, fresh 13F adds (World Inv echoes), ChartMill momentum catapults to $247....

Summary: Hold LONG—Piper Sandler initiates Overweight $270, 13F momentum (Signaturefd steady), ChartMill elite breakout to $246 ATH....

Summary: Hold LONG—Evercore ISI initiates Buy $268 street-high, 13F inflows (Merchants' Gate +25%), ChartMill breakout surges....

Summary: Hold LONG—RBC Capital initiates Outperform $265 on diagnostics surge, institutional net inflows, +5.8% position ATH grind....

Summary: Hold LONG—Leerink upgrades to Outperform $270, fresh 13F boosts (Cerity steady), ChartMill momentum intact pre-Q4....

Summary: Hold LONG—ChartMill RSI/momentum bullish, Q4 preview steady, SunriseTrader ups let it ride stops amid 12.51% upside potential....

Summary: Hold LONG—Citigroup upgrades to Buy $262, institutional inflows (Signaturefd +15%), +4.5% position into earnings hype....

Summary: Hold LONG—Barclays initiates Overweight $255 on biopharma recovery, fresh 13F adds, ChartMill momentum surges to $240....

Summary: Hold LONG—Stifel $260 Buy reaffirms DBS edge, 13F inflows (World +12%), +3.8% position gain amid healthcare lift....

Summary: Hold LONG—intraweek strength to $238 +3.4% gain, fresh 13F buys (World Inv +12%), consensus $253 PT builds to Q4....

Summary: Hold LONG—new year rally to $237 +2.8% gain, Wolfe/Jefferies upgrades stack, ChartMill breakout rolls on....

Summary: Hold LONG—year-end $235 +2% gain, Moderate Buy $253 PT, SunriseTrader let it rides signal conviction into 2026....

Summary: Hold LONG—up 1.3% to $234.50 intraday, Moderate Buy consensus $253 PT, SunriseTrader "let it rides" post-ex-div....

Summary: Hold LONG—SunriseTrader holds "let it rides" post-ex-div, ChartMill bullish setup, analysts $243-270 PTs amid year-end strength....

Summary: Exit long DHR near resistance at 235 after strong run-up from 215.79 entry, locking in gains amid overbought signals and no fresh catalysts, with next earnings around late January 2026....

Summary: Hold long on DHR as the uptrend persists with price at 231.04 above rising EMA 224.58 and SMA 221.32, positive MACD 2.11, RSI 59.6 not overbought, and gains from entry at 215.79 without breach of key support near 220 despite nearing resistance at 235....

Summary: Hold long on DHR as the uptrend continues with price at 230.74 above rising EMA 224.13 and SMA 220.82, positive MACD at 1.90, RSI 59.2 not overbought, and no compelling exit near resistance at 235 despite gains from entry at 215.79....

Summary: Hold long on DHR as the uptrend persists with price at 228.24 above rising EMA 223.69 and SMA 220.32, positive but weakening MACD at 1.67, RSI 56.1 not overbought, and no strong resistance breach or exit signal near 235 despite recent gains from entry at 215.79....

Summary: Hold long on DHR as the uptrend continues with price at 223.65 above rising EMA 223.30 and SMA 219.78, positive MACD 1.49, neutral RSI 49.7, and no compelling exit near resistance at 235 despite minor pullback....

Summary: Hold long on DHR as the uptrend persists with price at 224.62 above rising EMA 223.30 and SMA 219.40, positive MACD 1.81, RSI 51 neutral, and no exit trigger near resistance at 235 despite recent volatility....

Summary: Hold long on DHR as the uptrend continues with price at 224.65 above rising EMA 223.24 and SMA 218.73, positive MACD 2.60, RSI 51 neutral, and no compelling exit near resistance at 235 despite minor pullback....

Summary: Hold long on DHR as the uptrend persists with price at 227.84 above rising EMA 223.10 and SMA 218.46, positive MACD 2.97, RSI 56.00, and no exit signals near resistance at 235 despite recent consolidation....

Summary: Hold long on DHR as the uptrend remains intact with price at 227.4 above rising EMA 222.84 and SMA 218.22, positive MACD 3.20, RSI 55.68, and no clear exit signals near resistance at 235 despite today's bearish engulfing candle....

Summary: Hold long on DHR's strong uptrend with price at 231.39 above rising EMA 222.46 and SMA 217.86, bullish MACD 3.34 and RSI 63.41, positive momentum pushing toward resistance at 235 without clear exit triggers....

Summary: Hold long on DHR's continued uptrend with price at 229.52 above rising EMA 221.79 and SMA 217.47, bullish MACD 3.06 and RSI 61.29, positive momentum near resistance but no exit signals yet....

Summary: Hold long on DHR's sustained uptrend with price at 224.37 above rising EMA 221.33 and SMA 216.87, bullish MACD 3.01 and RSI 54.46, positive momentum without resistance breach or exit triggers....

Summary: Hold long on DHR's continued uptrend with price at 226.58 above rising EMA 220.91 and SMA 215.32, bullish MACD 3.74 and RSI 58.69, positive momentum testing resistance near 230 without immediate catalysts for exit....

Summary: Hold long on DHR's sustained uptrend with price at 226.78 above rising EMA 220.49 and SMA 214.41, bullish MACD 3.92 and RSI 59, positive momentum near recent highs, no earnings until late January 2026 or immediate negative catalysts....

Summary: Hold long on DHR's continued uptrend with price 228.76 above rising EMA 220.08/SMA 213.59, bullish MACD 4.12/RSI 62, positive momentum from recent highs, no earnings until late January 2026 or negative catalysts....

Summary: Hold long on DHR's sustained uptrend with price 227.3 above rising EMA 219.53/SMA 212.83, bullish MACD 4.15/RSI 61, positive momentum toward resistance at 252, no imminent earnings until late January 2026 or negative catalysts....

Summary: Hold long on DHR's continued uptrend with price 224.59 above rising EMA 219.02/SMA 212.10, bullish MACD 4.26/RSI 57.75, positive momentum from recent highs, no imminent earnings or negative catalysts, targeting resistance near 252....

Summary: Hold long on DHR's strong uptrend with price 226.98 above rising EMA 218.65/SMA 211.48, bullish MACD 4.59/RSI 62.2, positive momentum from recent breakout, no imminent earnings or negative catalysts, targeting resistance near 252....

Summary: Hold long on DHR's continued uptrend with price 228.32 above rising EMA 218.07/SMA 210.84, bullish MACD 4.67/RSI 64.83, momentum toward resistance at 252, no imminent earnings or negative catalysts after recent breakout....

Summary: Hold long on DHR's strong uptrend with price 230.84 above rising EMA 217.36/SMA 210.13, bullish MACD 4.60/RSI 69.87, recent breakout above prior highs targeting resistance at 252, no imminent earnings or negative catalysts....

Summary: Hold long on DHR's continued uptrend with price at 227.18 above rising EMA 216.45/SMA 209.33, bullish MACD 4.18/RSI 66.5, pushing toward resistance near 252 after holding support at 211, no imminent earnings or catalysts....

Summary: Hold long on DHR's sustained uptrend with price at 226.87 above rising EMA 215.67/SMA 208.55, bullish MACD 3.91/RSI 66.4, rebounding toward potential resistance at 252 after support at 211, no earnings until late January 2026....

Summary: Hold long on DHR's strong uptrend with price at 222.72 above rising EMA 214.94/SMA 207.82, positive MACD 3.62/RSI 61.92, pushing toward 252 resistance after rebound from 211 support, no near-term earnings or catalysts....

Summary: Hold long on DHR's continued uptrend with price at 221.67 above rising EMA 214.35/SMA 207.26, positive MACD 3.51/RSI 60.25, rebounding toward 252 resistance after holding 211 support, no immediate catalysts or earnings....

Summary: Hold long on DHR's strong uptrend with price at 225.96 above rising EMA 213.88/SMA 206.68, positive MACD 3.53/RSI 68.09, pushing toward 252 resistance after support at 211, no immediate catalysts....

Summary: Hold long on DHR's continued uptrend with price at 220.09 above rising EMA 213.02 and SMA 206.04, positive MACD 3.00/RSI 61.22, rebounding toward 225-252 resistance after support at 211, no earnings until January 2026 or major negative catalysts....

Summary: Hold long on DHR's strong uptrend with price at 222.36 above rising EMA 212.61 and SMA 205.64, positive MACD 3.00/RSI 64.76, rebound from 211 support targeting 225-252 resistance, no imminent earnings until January 2026 or negative catalysts....

Summary: Hold long on DHR's continued uptrend with price at 222.21 above rising EMA/SMA, positive MACD/RSI momentum, rebound from support near 211, targeting resistance at 225-252 over weeks, no imminent earnings or negative catalysts....

Summary: Hold long on DHR's strong uptrend continuation with price surging above rising EMA/SMA to 219.32, positive momentum from improving RSI/MACD, rebound from support, and no imminent catalysts, targeting resistance near 225-252 over weeks despite past volatile exits....

Summary: Enter long on DHR's confirmed uptrend with price above rising EMA/SMA, rebound above prior support at 211 after recent exit, positive momentum signals like improving MACD/RSI, and favorable risk/reward targeting resistance near 225 over weeks, justified quick re-entry due to sustained recovery and no lingering fade. This aligns with avoiding entries in downtrends or rangebound periods, and the recent volume on the bounce (e.g., 1.76M on 11/11) supports conviction without capitulation needed since it's not a downtrend reversal....

Summary: Stay in cash as the trend is unclear with price crossing the EMA twice in the past month, recent MACD bearish below signal line, and no high-confidence setup for entry following the quick recovery from support after the prior exit on fading momentum. The stock pulled back to 209.94 on 11/7, breaching minor support around 211 as noted in the last trade exit, but has since recovered to 211.49, holding above that level with neutral RSI at 51 and low Stochastic K at 19 suggesting potential oversold bounce. However, MACD at 1.82 remains below the signal at 3.12 and declining, indicating weakening momentum and risk of further pullback, especially after the post-earnings rally from 10/21 peaked at 223 and faded. Support holds at 181.94 with historical strength, while resistance is distant at 252.95, but the chart shows consolidation in a 210-223 range lately, with no clear breakout....

Summary: Stay in cash for DHR as technicals show unclear uptrend with price at EMA, recent support breach below 211, fading momentum post-earnings, and no compelling new info for quick re-entry after 11/6 exit....

Summary: Exit long DHR as price breached key support below 211 with fading post-earnings momentum and no major catalysts ahead, locking in position amid unclear upside potential....

Summary: Hold long on DHR as uptrend continues with price above rising EMA/SMA, no support breach below 211, momentum from post-earnings gap and biotech sector strength, targeting 252 resistance amid no imminent catalysts....

Summary: Hold long on DHR as uptrend persists with price above rising EMA/SMA, no breach of 211 support, sustained momentum from earnings gap-up and biotech tailwinds, targeting 252 resistance with no near-term catalysts....

Summary: Hold long on DHR as uptrend continues with price above rising EMA/SMA, no breakdown below key 213 support, positive momentum from recent earnings beat and biotech sector strength, targeting 252 resistance amid stable fundamentals without imminent catalysts....

Summary: Hold long on DHR as uptrend persists with price above rising EMA/SMA, no breakdown below 213 support trendline, positive momentum from earnings and biotech sector tailwinds, targeting 252 resistance without near-term catalysts....

Summary: Hold long on DHR amid sustained uptrend with price above rising EMA/SMA, no breakdowns below key supports like 214 trendline, positive momentum from recent earnings beat persisting without near-term catalysts, targeting resistance near 252....

Summary: Hold long on DHR's continued uptrend with price above rising EMA/SMA, no breakdowns below key supports, positive post-earnings momentum persisting, and targeting 252 resistance without imminent catalysts....

Summary: Hold long on DHR's intact uptrend with price above rising EMA/SMA, positive momentum from 10/21 earnings gap, no breakdowns or immediate catalysts, targeting 252 resistance amid broader market stability....

Summary: Hold long on DHR's continued uptrend with price above rising EMA/SMA, positive post-earnings momentum from 10/21 gap, targeting 252 resistance, and no immediate catalysts or breakdowns signaling exit....

Summary: Hold long on DHR's strong uptrend post-earnings gap, with price above rising EMA/SMA, positive momentum targeting 252 resistance, and no immediate catalysts or breakdowns....

Summary: Hold long on DHR's confirmed uptrend with price above EMA/SMA post-earnings gap up, positive momentum despite minor pullback, targeting resistance near 252 amid no immediate catalysts....

Summary: Enter long on DHR's strong post-earnings gap up in a confirmed uptrend with price above EMA/SMA, positive reaction despite 0% surprise, targeting resistance near 252 over weeks, justified re-entry soon after 10/16 exit due to new favorable earnings outcome and momentum shift....

Summary: Stay in cash to avoid entering right before DHR's Q3 earnings on 10/21/2025, with technicals showing an uptrend but no high-confidence setup for a multi-week hold amid potential volatility, and past trade history indicating risks of post-earnings pullbacks without meeting hold-through criteria....

Summary: Uptrend confirmed with price above EMA/SMA, but upcoming earnings on 10/21/2025 without meeting hold-through criteria prevent new long entry to avoid catalyst risk, while biotech nature bars shorting, so stay in cash awaiting post-earnings setup....

Summary: Exiting long DHR position near recent highs at 210.39 ahead of earnings on 10/21/2025 due to unmet surprise criteria, with price approaching resistance around 216 while uptrend remains intact but no major catalysts post-earnings to justify holding through volatility....

Summary: Holding long on DHR's confirmed uptrend with price at 206.57 above EMA 201.26 and SMA 200.95, positive MACD 2.59, RSI 56 neutral, ongoing bounce from capitulation without breakdown, while planning exit near resistance 216 before earnings on 10/21/2025 due to unmet surprise criteria....

Summary: Danaher's stock shows strong long-term fundamentals and recent support levels, making it a solid hold for potential upside....

Summary: Holding long on DHR as the bounce from capitulation low continues with price at 205.32 above EMA/SMA around 200-201, positive MACD at 2.52, RSI 55 neutral, and no breakdown to supports like 182, while monitoring resistance at 216 and planning exit before earnings on 10/21/2025 due to unmet surprise criteria....

Summary: Holding long on DHR as the bounce from capitulation low at $184.84 holds with price at 202.96 above key supports like 198-200 and EMA/SMA around 200, positive MACD at 2.56 signaling momentum, RSI at 52.8 neutral, and no breakdowns despite unclear trend with EMA slightly below SMA, while monitoring for resistance at 216 ahead of earnings on 10/21/2025....

Summary: Holding long on DHR as the bounce from capitulation low at $184.84 continues with price above key supports around 198-200, positive MACD at 2.72 signaling upward momentum, RSI at 54 indicating balanced strength, and no immediate catalysts or breakdowns despite unclear trend with EMA slightly below SMA. Technicals prioritize here: EMA at 200.02 is below SMA at 200.34, but price remains above both, suggesting an unclear trend rather than a downtrend reversal—I'm not exiting solely on that, as the position was entered on capitulation strength. MACD is positive at 2.72 with the line above signal, and RSI at 53.76 avoids overbought territory, supporting continued momentum. Stochastic K at 75.02 and D at 75.50 show room for upside without exhaustion....

Summary: Holding long on DHR as the bounce from capitulation low holds above key supports like 198-200 with positive MACD crossover and RSI at 55 signaling momentum, despite unclear trend from EMA below SMA, and earnings on 10/21/2025 still over a week away with no immediate catalysts found....

Summary: Holding long on DHR as the breakout from capitulation low continues with price holding above rising supports around 196-200, positive momentum indicators like RSI at 59 and MACD improving, no compelling exit signals despite unclear trend from EMA slightly below SMA, and earnings still two weeks away....

Summary: Holding long on DHR as the breakout momentum from capitulation low persists with price above key supports and pulling back mildly near $216 resistance on positive indicators, no strong exit signals yet ahead of earnings....

Summary: Holding long on DHR as the breakout from capitulation low continues with price surging to near $216 resistance on high volume and positive momentum, no immediate exit signals despite unclear trend, targeting further upside before earnings....

Summary: Holding long on DHR amid strong breakout momentum from capitulation low, price above EMA/SMA targeting $216 resistance, with positive news catalysts and no immediate exits warranted....

Summary: Holding long on DHR after strong breakout to $211.20 on high volume from capitulation low, with price above EMA/SMA targeting $216 resistance, no immediate catalysts, and positive momentum overriding unclear trend signals....

Summary: Holding long on DHR as the volume capitulation bounce from $181.35 low continues with price closing at $197.14 above EMA in a recovering trend, targeting resistance near $205-216, supported by RSI 53.8 and no invalidation after 3 trading days....

Summary: Holding long on DHR after volume capitulation bounce from $181.35 low, with price at $186.06 showing early recovery in downtrend toward resistance at $205-216, supported by oversold RSI 38 and no invalidation yet. Today's close at $186.06 represents a modest rebound, aligning with historical patterns where DHR has bounced from oversold levels (e.g., RSI around 30-40) after high-volume selloffs, as seen in April 2025 when it dropped to $174.64 and recovered to $199 over weeks....

Summary: Enter long on DHR's volume capitulation at oversold levels in a downtrend, with support near 182 holding and potential bounce to resistance around 205-216 over weeks, despite recent losses from early exits. RSI at 35 indicates oversold conditions, Stochastic K at 11.7 supports a bottom, and volume at 3.36M is moderate but flagged, with the low of 181.35 near the support level of 181.94 (strength 3, last tested in April 2025). This setup mirrors past oversold bounces in the trade history, like the July 18 entry at 190 that aimed for 205 resistance but was cut short by earnings—here, no immediate catalysts interfere....

Summary: Stay in cash as DHR is in a clear downtrend without volume capitulation, precluding long entries, while its biotech and M&A exposure makes shorting too risky despite favorable technicals for a potential short....

Summary: Stay in cash as DHR remains in a confirmed downtrend with EMA below SMA and price below both, no volume capitulation for a long entry, and shorting is avoided due to its biotech exposure risking sudden upside news....

Summary: Stay in cash as DHR is in a clear downtrend with EMA below SMA and price below both, no recent volume capitulation to justify a long entry against the trend, and shorting is prohibited for this biotech-related stock given potential for sudden positive news spikes....

Summary: Stay in cash as DHR is in a confirmed downtrend with price below both EMA and SMA, no volume capitulation for a long entry, and shorting is avoided due to its biotech exposure risking sudden upside from news....

Summary: Stay in cash as DHR is in a downtrend with EMA below SMA and price below both, no volume capitulation for long entry, and shorting biotech stocks is avoided due to high spike risk on news....

Summary: Stay in cash as DHR remains in a clear downtrend with price below EMA and SMA, no volume capitulation for a long entry, and shorting biotech stocks like DHR is avoided due to high spike risk on news....

Summary: Stay in cash as DHR is in a downtrend with an unclear trend due to tightly rangebound EMA and SMA without volume capitulation, avoiding new entries per technical rules, while no high-conviction setups emerge from chart patterns or external factors....

Summary: Stay in cash as DHR is in a confirmed downtrend with price below both EMA and SMA, no volume capitulation for a long entry, and as a biotech stock it's too risky to short despite the downtrend, with current levels near strong support around 187-189 avoiding poor entries....

Summary: Stay in cash as DHR's technicals show an unclear trend with EMA slightly below SMA and tightly rangebound, price below both indicating potential downtrend without volume capitulation, recent support at 189.88 holding but no high-confidence setup for long or short entry given avoidance of shorts on biotech stocks and past failed longs in similar weakening conditions....

Summary: Stay in cash as the trend is unclear with EMA and SMA tightly rangebound and frequently crossing, price below both without volume capitulation, and no high-confidence setup for entry despite proximity to support levels around 189-192....

Summary: Stay in cash as DHR's trend is unclear with EMA slightly above SMA but price below both, no volume capitulation, and recent downtrend continuation without high-confidence reversal signals, targeting better entry opportunities near supports like 189.88 over the next few weeks....

Summary: Stay in cash as the trend is unclear with price below both EMA and SMA despite EMA above SMA, no volume capitulation for a long entry in this setup, and DHR's biotech exposure prohibits shorting, while recent price action shows a pullback from resistance without strong bullish catalysts....

Summary: Stay in cash as DHR's trend is unclear with price below both EMA and SMA despite EMA slightly above SMA, no volume capitulation, and recent pullback without high-confidence long or short setup amid rangebound action targeting support near 194-189 over the next few weeks....

Summary: Stay in cash as the trend is unclear with EMA above SMA but price below both, frequent crossings in the past month without volume capitulation, and no high-confidence setup for entry despite oversold indicators like Stochastic K at 13, while avoiding shorts on this biotech-related stock....

Summary: Stay in cash due to unclear trend with price below both EMA and SMA despite EMA above SMA, no volume capitulation, recent exit from long on 9/2 after failure to break resistance near 216, and no high-confidence setup for re-entry so soon without new bullish catalysts or trend confirmation....

Summary: Stay in cash as the trend is unclear with EMA above SMA but price below both, no volume capitulation, and recent price weakness without a clear uptrend or high-confidence dip-buying opportunity, while avoiding shorts on this biotech-related stock....

Summary: Exit long on DHR as price has dipped below EMA in a weakening uptrend with no volume capitulation, recent failure to break resistance near 216, and momentum indicators like RSI at 48 showing loss of upside steam, targeting risk management ahead of potential further pullback to supports around 190-200 over the next few weeks....

Summary: Hold long on DHR as the confirmed uptrend persists with price above EMA and SMA, recent pullback holding support near 204 while building towards 216 resistance, no imminent catalysts or volume capitulation, and positive momentum indicators supporting further upside over the next few weeks....

Summary: Hold long on DHR as the uptrend remains confirmed with price above EMA and SMA, building momentum towards 216 resistance after holding support near 204, no volume capitulation or imminent catalysts, and positive sector trends....

Summary: Hold long on DHR as the confirmed uptrend persists with price above EMA and SMA, momentum building towards 216 resistance after recent pullback support at 204, no imminent catalysts or volume capitulation, and positive healthcare sector trends from recent acquisitions....

Summary: Hold long on DHR as the uptrend continues with price above EMA and SMA, recent momentum pushing towards 216 resistance, no volume capitulation or catalysts, and positive sector tailwinds....

Summary: Hold long on DHR as the uptrend persists with price above EMA and SMA, positive momentum from recent breakout above 200-208 resistance targeting 216, no volume capitulation or imminent catalysts, and supportive fundamentals in life sciences sector....

Summary: Hold long on DHR as the uptrend remains confirmed with price above EMA and SMA, recent breakout above prior resistance near 208 targeting next levels around 216, supported by positive momentum and no imminent catalysts. The current position entered 13 bars ago at $199.04 has appreciated to $212.4, meeting the minimum hold period while capturing a bigger multi-week move from support around $190-200, and simulation of similar setups in early 2025 (like the bounce from April lows) suggests high win rates with sustained rallies above key moving averages, avoiding past mistakes like early exits on temporary pullbacks seen in July trades....

Summary: Hold long on DHR as the confirmed uptrend persists with price above EMA and SMA, pulling back from recent highs near 212 but holding above key supports around 200-202, targeting resistance at 216 with no imminent catalysts....

Summary: Hold long on DHR as the uptrend continues with price above EMA and SMA, momentum building towards 216 resistance after recent highs above 210, no imminent earnings or reversals, maintaining the 8/5 entry at $199.04 now at 11 bars with current close at 211.08....

Summary: Hold long on DHR as the uptrend persists with price above EMA and SMA, recent momentum pushing towards 216 resistance after breakout from 205, and no earnings or reversals imminent, maintaining the 8/5 entry at $199.04 now at 10 bars....

Summary: Hold long on DHR as uptrend continues with price above EMA and SMA, recent breakout above 205 resistance holding with closes near 210, minimum 10-14 day hold from 8/5 entry ongoing at 9 bars, and no immediate earnings or trend reversals....

Summary: Hold long on DHR as uptrend persists with price above EMA/SMA, recent breakout above 205 resistance holding firm, minimum 10-14 day hold from 8/5 entry not fully met yet, and no immediate catalysts or trend breakdowns....

Summary: Hold long on DHR as uptrend remains with price above EMA/SMA, recent closes near 210 after breakout above 205 resistance, minimum hold period from 8/5 entry not yet met, and no immediate catalysts....

Summary: Hold long on DHR as the uptrend persists with price above EMA and SMA, recent breakout above 205 resistance to 209 close, minimum 10-14 day hold from 8/5 entry at 199.04 not yet fully met, and no catalysts or trend invalidation....

Summary: Hold long on DHR as uptrend continues with price above EMA/SMA, recent close at 205.34 nearing 205 resistance after bounce from 197 support, minimum 10-14 day hold from 8/5 entry not yet met, and no immediate catalysts....

Summary: Hold long on DHR as uptrend persists with price above EMA/SMA, ongoing bounce from 197 support aiming for 205 resistance, no near-term catalysts, and minimum 10-14 day hold from 8/5 entry at $199.04 not yet fulfilled despite minor pullbacks. This aligns with the prior entry rationale, targeting resistance at $205.48, which has strong historical significance with 6 bounces. Volume on 8/11 was moderate at 1.68M, and indicators like RSI (51.71) suggest neutral momentum without overbought conditions, while SlowSTO_K (50.71) is building from oversold levels, supporting continued upside potential over weeks....

Summary: Hold long on DHR as uptrend remains confirmed with price above EMA/SMA, recent bounce from 197 support targeting 205 resistance, no immediate catalysts like earnings (next on Oct 28, 2025), and minimum hold period of 10-14 days not yet met from 8/5 entry at $199.04 despite minor fluctuations....

Summary: Hold long on DHR in confirmed uptrend with price above EMA/SMA, recent bounce from support near 197 targeting resistance at 205, no immediate catalysts, and minimum hold period not yet met despite minor pullback....

Summary: Hold long on DHR despite pullback below EMA/SMA as position is only 1 day old requiring minimum 10-14 day hold, with unclear trend but potential bounce toward 205 resistance amid positive long-term sentiment and no immediate catalysts....

Summary: Enter long on DHR's confirmed uptrend with price above EMA/SMA, recent bounce from pullback support around 197, positive momentum signals like power inflow, and targeting resistance near 205 over the next few weeks while monitoring for sustained strength....

Summary: Stay in cash as the trend is unclear with EMA and SMA tightly rangebound without clear direction, avoiding new entries despite recent post-earnings momentum fading near resistance. Recent news from sources like Yahoo Finance and Benzinga highlights a key trading signal with the stock closing near highs at $193.11 last week, but softer Q2 profits and executive changes (CFO transition in Feb 2026, General Counsel departure Aug 25, 2025) add uncertainty without overriding technicals. Posts on X reflect long-term optimism on Danaher's business system and growth, but short-term sentiment is neutral. No volume capitulation flagged, and we're near support at $186 but below resistance at $205 with strong historical bounces there—simulating past setups like the July pullback shows risk of further downside or whipsaw, as our recent trades exited at losses due to similar weakening momentum. Cannot short due to Danaher's biotech exposure. Next earnings likely Q3 in October, no immediate catalysts within 3 days. Overall, better to wait for a clearer trend or dip in confirmed uptrend for a high-confidence long entry targeting $205+ over weeks.

Summary: Stay in cash as the trend is unclear with EMA slightly above SMA but price below both, frequent price crossings without volume capitulation, and recent long trades resulted in losses amid weakening momentum post-earnings....

Summary: Exit long DHR position as the post-earnings uptrend has weakened with price below EMA, unclear trend from frequent crossings, softer Q2 profits, and pullback nearing support around $186 without volume capitulation, prioritizing risk management over minimum hold amid negative momentum....

Summary: Hold long on DHR's sustained uptrend post-earnings with price above EMA/SMA, positive FY25 guidance, accelerating revenue consensus, and targeting resistance near $216 over the next few weeks without near-term catalysts....

Summary: Hold long on DHR's continued post-earnings uptrend with price above EMA/SMA, recent breakout above $205 resistance, raised FY25 guidance, and no near-term catalysts, targeting further gains toward $216 over the coming weeks....

Summary: Continue holding the long position in DHR amid a confirmed uptrend with positive post-earnings momentum from beaten estimates and raised guidance, targeting a breakout above $205 resistance while monitoring for sustained strength....

Summary: Hold long on DHR's continued post-earnings strength with beaten estimates, raised guidance, uptrend intact above EMA/SMA, and breakout above $205 resistance, targeting further upside over weeks without immediate catalysts....

Summary: Enter long on DHR's post-earnings momentum in a confirmed uptrend with beaten estimates, raised FY25 guidance, and no immediate catalysts, targeting potential breakout above $205 resistance over the next few weeks while monitoring for sustained closes above EMA/SMA....

Summary: Stay in cash as the trend is unclear with EMA and SMA tightly rangebound, avoiding new entries post-earnings despite positive results, while waiting for a better dip after recent loss exit....

Summary: Upcoming earnings on 7/23/2025 pose high risk of volatility, trend is unclear with EMA slightly above SMA but price below both and no volume capitulation, while oversold indicators tempt a bounce but recent early exit loss on similar pre-earnings setup advises staying sidelined for better post-catalyst entry....

Summary: Exit long DHR position early due to imminent Q2 earnings on 7/23/2025 with high risk of negative reaction based on historical post-earnings drops, despite oversold indicators and no clear downtrend invalidation yet, prioritizing catalyst avoidance over minimum hold period. ...

Summary: Long DHR as it's oversold with RSI at 38, Stochastic K at 15, and close below Bollinger lower band near recent lows around 184-190, setting up a high-confidence bounce to resistance at 205 over the next few weeks with favorable risk/reward from current levels around 190....